85 related articles for article (PubMed ID: 21875020)
1. [Golimumab (Simponi)--first subcutaneous anti-TNF with once-monthly application].
Babić-Naglić D; Anić B; Novak S
Reumatizam; 2010; 57(2):154-5. PubMed ID: 21875020
[No Abstract] [Full Text] [Related]
2. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies.
Hutas G
Immunotherapy; 2010 Jul; 2(4):453-60. PubMed ID: 20635999
[TBL] [Abstract][Full Text] [Related]
3. Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
[No Abstract] [Full Text] [Related]
4. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis.
McCluggage LK; Scholtz JM
Ann Pharmacother; 2010 Jan; 44(1):135-44. PubMed ID: 20118145
[TBL] [Abstract][Full Text] [Related]
5. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
6. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
7. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
8. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
Buch MH; Marzo-Ortega H; Bingham SJ; Emery P
Rheumatology (Oxford); 2004 Feb; 43(2):243-4. PubMed ID: 14739466
[No Abstract] [Full Text] [Related]
11. By the way, doctor. I've heard about a new rheumatoid arthritis drug that I'd only have to take every two weeks. What do you know about it?
Robb-Nicholson C
Harv Womens Health Watch; 2003 May; 10(9):8. PubMed ID: 12763730
[No Abstract] [Full Text] [Related]
12. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological and clinical profile of golimumab (Simponi®)].
Fujii H; Murakami Y; Harada Y
Nihon Yakurigaku Zasshi; 2013 May; 141(5):275-85. PubMed ID: 23665559
[No Abstract] [Full Text] [Related]
15. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
Dermatology; 2008; 217(4):380. PubMed ID: 18849606
[No Abstract] [Full Text] [Related]
16. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
[TBL] [Abstract][Full Text] [Related]
17. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
Actis GC; Lagget M; Pellicano R; Rosina F
Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
[No Abstract] [Full Text] [Related]
18. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
[No Abstract] [Full Text] [Related]
19. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
[No Abstract] [Full Text] [Related]
20. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
Wollheim FA
Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
[No Abstract] [Full Text] [Related]
[Next] [New Search]